Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response

Laboratory Investigation

Volumn 74, Issue 1, 1996, Pages 43-47

  Mihm Jr , Martin C ^a   Clemente, Claudio G ^b   Cascinelli, Natale ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELLULAR IMMUNITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

BIOLOGICAL RESPONSE MODIFIERS; HUMANS; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 0030052833     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosemberg SA, Adema GJ, and Figdor CG (1994). Melanocyte lineage-specific antigen gp 100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009.
2. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, and Itoh K (1990). Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125:200-205.
3. Balch CM, Soong S, Shaw HM, Vrist MM, and McCarthy WH (1992). An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, and Soong S, editors. Cutaneous melanoma, 2nd ed. Philadelphia: Lippincott, 176-180.
4. Black MM, Opler SR, and Speer FD (1956). Structural representations of tumor-host relationship in gastric carcinoma. Surg Gynecol Obstet 102:599-603.
5. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, and Boon T (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A 2 melanomas. J Exp Med 178:489-495.
6. Cascinelli N, Bufalino R, Morabito A, and MacKie R (1994). Results of adjuvant interferon study in WHO melanoma programme. Lancet 343:913-914.
7. Cascinelli N, Morabito A, Bufalino R, van Esch EP, Preda F, Vaglini M, Rovini D, and Orefice S (1980). Prognosis of stage I melanoma of the skin. Int J Cancer 26:733-739.
8. Clark WH, Elder DE, Guerry DPIV, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, and Halpern AC (1989). Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893-1904.
9. Clemente C and Collini P (1993). TIL as prognostic histopathologic parameter in cutaneous melanoma. Melanoma Res 3:26.
10. Cox DR (1972). Regression models and life tables (with discussion). J Roy Stat Soc B 34:187-220.
11. Dixon FJ and Moore RA (1953). Testicular tumors: A clinicopathological study. Cancer 6:427-454.
12. Elder DE, Guerry D IV, Van Horn M, Hurwitz S, Zehngebot L, Glodman LI, LaRossa D, Hamilton R, Bondi EE, and Clark WH Jr (1985) The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 56:413-418.
13. Elston CW (1969). Cellular reaction to choriocarcinoma. J Pathol 97:261-268.
14. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, and Boon T (1994). Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolitic lymphocytes. J Exp Med 179:921-930.
15. Lipponen PK, Eskelinen Mj, Janhiainen K, Harju E, and Terho R (1993). Tumor infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 29A:69-75.
16. Lucin K, Iternicka Z, and Jonjic N (1994). Prognostic significance of T-cell infiltrates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma. Pathol Res Pract 190:1134-1140.
17. Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data froma retrospective studies of disease. J Natl Cancer Inst 22:719-748.
18. Martin RF and Beckwith JB (1968). Lymphoid infiltrates in neuroblastoma: Their occurrence and prognostic significance. J Pediatr Surg 3:161-164.
19. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, and Smith PG (1976). Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Part I - Introduction and design. Br J Cancer 34:585-612.
20. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, and Smith PG (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient: Part II - Analysis and examples. Br J Cancer 35:1-39.
21. Poppema S, Brocker EB, de Leij L, Terbroek D, Visscher T, Ter Haar A, Macher E, The TH, and Sorg C (1983). In situ analysis of the mononuclear cell infltrate in primary malignant melanoma of the skin. Clin Exp Immunol 51:77-82.
22. Ridley A and Cavanagh JB (1971). Lymphocytic infiltration in gliomas: Evidence of possible host resistence. Brain 94:117-124.
23. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Delia Porta G, Ménard S, Pierotti MA, and Testori A (1991). Prognostic significance of HER-2/NEU expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49.